Attestation committee
Accreditation committee
Expert committee
Dispositions, instructions
Normative acts
Nomenclature
Institutions
Scientific councils
Seminars
Theses
Scientific advisers
Scientists
Doctoral students
Postdoctoral students
CNAA logo

 română | русский | english

CNAA / Theses / 2010 / June /

Acute and chronic viral hepatitis C, B and D. Clinical particularities, epidemiological, immune and treatment aspects


Author: Pântea Victor
Degree:doctor habilitat of medicine
Speciality: 14.00.10 - Infections Diseases
Year:2010
Scientific consultants: Constantin Andriuţă
doctor habilitat, professor, State University of Medicine and Pharmacy "Nicolae Testemitanu"
Constantin Spînu
doctor habilitat, professor, National Center of Public Health
Institution: State University of Medicine and Pharmacy "Nicolae Testemitanu"
Scientific council: DH 50-14.00.10-27.03.08
State University of Medicine and Pharmacy "Nicolae Testemitanu"

Status

The thesis was presented on the 9 June, 2010
Approved by NCAA on the 5 July, 2010

Abstract

Adobe PDF document0.74 Mb / in romanian

Keywords

Viral hepatitis C, B, and D, pacovirine, pegasys, copegus. lamivudin, imuheptin, imupurin, cytomix, guna liver, interferon gamma

Summary

Scope of work consists in the determination of clinical, epidemiological, immune particularities and evolution of patients with viral hepatitis C,. B and D in acute and chronic forms. Monitoring of evolution and appreciation of efficiency of various antiviral, immune modulation and hepatic protection medicines in the treatment of such patients. Objectives of work: study of clinical, epidemiological, immune diagnostic and treatment particularities of acute viral hepatitis C, B and D. Detection of viral hepatitis B and D at pregnant women and hearth family. Determination of clinical, biochemical, serological and evolution particularities at patients with chronic viral hepatitis C, B and D. Determination of efficiency of antiviral treatment (with viferon. Intron A, infergen. realdiron, pegasys, copegus, lamivudin) and immunomodulation drugs: hepatito-lyz, imuheptin, imupurin, cytomix, guna liver, interferon gamma at patients with the chronic viral hepatitis C, B and D.

The study covered 236 patients with acute viral hepatitis C and 368 with acute viral hepatitis B. Were examined HBsAg 4766 analyses from 9 risk groups and 2158 pregnant women, 435 persons from 165 niduses with hepatitis B and D in acute and chronic forms, 336 patients with CVHC, 280 with CVHB and 260 with CHVD.

Was confirmed the importance of RNA-HVC study and anti-VHC spectrum in the early diagnostics of AVHC. The conducted studies have demonstrated that AVHC was determined by the Ib genotype (95,5%). For the first time was justified the need to treat the patients with AVHC with pacovirin, pegasys and copegus at patients with AVHC. For the first time in Moldova, simultaneously with the artificial transmission ways of viral hepatitis B were established the natural ones, as there has been attested a mechanism of maternal-fetal transmission. The studies demonstrate a wide spread of not only viral hepatitis B, but also of the viral hepatitis D in the Republic of Moldova.

For the first time was demonstrated the efficiency of various antiviral drugs: viferon, intron A, realdiron, Infergen, pegasys, copegus, lamivudin and immune modulation drugs: hepatito-lyz. imuheptin, imupurin, cytomix, guna liver, interferon gamma in the treatment of patients with chronic viral hepatitis C, B and D.